Holman RR - Search Results

1

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.

Angwin C, Jenkinson C, Jones A, Jennison C, Henley W, Farmer A, Sattar N, Holman RR, Pearson E, Shields B, Hattersley A; MASTERMIND consortium. Angwin C, et al. Among authors: holman rr. BMJ Open. 2020 Dec 21;10(12):e042784. doi: 10.1136/bmjopen-2020-042784. BMJ Open. 2020. PMID: 33371044 Free PMC article.

2

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).

Holman RR, Cull CA, Turner RC. Holman RR, et al. Diabetes Care. 1999 Jun;22(6):960-4. doi: 10.2337/diacare.22.6.960. Diabetes Care. 1999. PMID: 10372249 Clinical Trial.

3

Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes.

Gloyn AL, Desai M, Clark A, Levy JC, Holman RR, Frayling TM, Hattersley AT, Ashcroft SJ. Gloyn AL, et al. Among authors: holman rr. Diabetologia. 2002 Apr;45(4):580-3. doi: 10.1007/s00125-002-0779-8. Diabetologia. 2002. PMID: 12032636

4

PROactive study.

Holman RR, Retnakaran R, Farmer A, Stevens R. Holman RR, et al. Lancet. 2006 Jan 7;367(9504):25-6; author reply 26-7. doi: 10.1016/S0140-6736(06)67914-2. Lancet. 2006. PMID: 16399144 No abstract available.

5

The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults.

Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, Hitman GA, Walker M, Holman RR, McCarthy MI, Clark A. Desai M, et al. Among authors: holman rr. Diabetes. 2006 Jun;55(6):1890-4. doi: 10.2337/db06-0089. Diabetes. 2006. PMID: 16731859

6

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes.

Hartweg J, Farmer AJ, Holman RR, Neil HA. Hartweg J, et al. Among authors: holman rr. Diabetologia. 2007 Feb;50(2):250-8. doi: 10.1007/s00125-006-0486-y. Epub 2006 Nov 21. Diabetologia. 2007. PMID: 17119918

7

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes.

Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Hartweg J, et al. Among authors: holman rr. Diabetologia. 2007 Aug;50(8):1593-602. doi: 10.1007/s00125-007-0695-z. Epub 2007 May 31. Diabetologia. 2007. PMID: 17541540 Review.

8

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC; 4-T Study Group. Holman RR, et al. N Engl J Med. 2007 Oct 25;357(17):1716-30. doi: 10.1056/NEJMoa075392. Epub 2007 Sep 21. N Engl J Med. 2007. PMID: 17890232 Free article. Clinical Trial.

9

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.

Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group. Holman RR, et al. Diabetologia. 2009 Jan;52(1):50-9. doi: 10.1007/s00125-008-1179-5. Epub 2008 Nov 11. Diabetologia. 2009. PMID: 19002433 Clinical Trial.

10

Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes.

Hartweg J, Farmer AJ, Holman RR, Neil A. Hartweg J, et al. Among authors: holman rr. Curr Opin Lipidol. 2009 Feb;20(1):30-8. doi: 10.1097/mol.0b013e328321b3be. Curr Opin Lipidol. 2009. PMID: 19133409

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

358 results

Search Page